Showing papers by "Hennie R. Hoogenboom published in 1996"
TL;DR: This diabody format, when combined with the power of phage display technology, allows the generation and analysis of thousands of different bispecific molecules and selection for binding presumably also selects for more stable diabodies.
Abstract: Methods for the generation of large numbers of different bispecific antibodies are presented. Cloning strategies are detailed to create repertoires of bispecific diabody molecules with variability on one or both of the antigen binding sites. This diabody format, when combined with the power of phage display technology, allows the generation and analysis of thousands of different bispecific molecules. Selection for binding presumably also selects for more stable diabodies. Phage diabody libraries enable screening or selection of the best combination bispecific molecule with regards to affinity of binding, epitope recognition and pairing before manufacture of the best candidate.
109 citations
TL;DR: This rapid concentration determination method will be particularly useful for accurately comparing affinity constants, using antibody concentrations determined with the BIAcore, of the many different scFv fragments routinely isolated from phage display libraries.
44 citations
TL;DR: Human single-chain gene transduced T cells were shown to express the scFv on their surface, to recognize their relevant ligand (tumor-associated antigen) on tumor target cells, to produce cytokines and, to lyze tumor cells.
Abstract: In summary, human single-chain gene transduced T cells were shown: to express the scFv on their surface, to recognize their relevant ligand (tumor-associated antigen) on tumor target cells, to produce cytokines and, to lyze tumor cells. In our earlier review on retargeting T lymphocyte specificity [11], we concluded that a number of questions needed to be answered: (1) Is triggering of cytolysis by CTL or lymphokine production most important to generate anti-cancer effects? Both are important, especially to eliminate bystander cells which do not express tumor-associated antigen [35, 75, 83, 106]. (2) Can targeted CTL traffick and home to the tumor site? Yes, they can. (3) Does “humanization” of mouse mAbs reduce HAMA responses? Our preliminary experiences suggest that this is the case (unpublished data). Significant progress has therefore been made in the laboratory and in clinical tests, and will continue to be made. We are now preparing for the clinical phase I/H testing of in vivo anti-tumor activity of T lymphocytes retargeted by transfer of chimeric receptor genes encoding Ab-type specificity.
15 citations